BRVEBraveheart Bio, Inc.
Insider trading & SEC Form 4 activity — last 90 days. Latest filing: 2026-08-11.
Insider buys (90d)
$482.67M
Insider sells (90d)
$0.00
Net flow
$482.67M
Filings
11
Buy transactions
26
Sell transactions
0
Distinct insiders
19
Last close (cached)
$28.91
as of 2026-09-09
1d return
-1.7%
5d return
+10.0%
1m return
+5.0%
Top insiders trading BRVE (90d)
Recent transactions (43)
| Filed | Txn date | Insider | Code | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-08-11 | 2026-08-07 | AH Bio Fund IV, L.P. | Buy | 1,100,000 | $18.00 | $19.80M | open → |
| 2026-08-11 | 2026-08-07 | AH Equity Partners Bio IV, L.L.C. 10% | Buy | 1,100,000 | $18.00 | $19.80M | open → |
| 2026-08-11 | 2026-08-07 | Andreessen Marc L 10% | Buy | 1,100,000 | $18.00 | $19.80M | open → |
| 2026-08-11 | 2026-08-07 | HOROWITZ BENJAMIN A 10% | Buy | 1,100,000 | $18.00 | $19.80M | open → |
| 2026-08-11 | 2026-08-07 | HOROWITZ BENJAMIN A 10% | C | 9,132,420 | $0.00 | $0.00 | open → |
| 2026-08-11 | 2026-08-07 | Andreessen Marc L 10% | C | 9,132,420 | $0.00 | $0.00 | open → |
| 2026-08-11 | 2026-08-07 | AH Equity Partners Bio IV, L.L.C. 10% | C | 9,132,420 | $0.00 | $0.00 | open → |
| 2026-08-11 | 2026-08-07 | AH Bio Fund IV, L.P. | C | 9,132,420 | $0.00 | $0.00 | open → |
| 2026-08-11 | 2026-08-07 | Chimovits Erez Director10% | Buy | 273,333 | $18.00 | $4.92M | open → |
| 2026-08-11 | 2026-08-07 | Chimovits Erez Director10% | Buy | 1,666,667 | $18.00 | $30.00M | open → |
| 2026-08-11 | 2026-08-07 | Chimovits Erez Director10% | C | 9,132,420 | $0.00 | $0.00 | open → |
| 2026-08-11 | 2026-08-07 | ORBIMED ADVISORS LLC Director10% | Buy | 273,333 | $18.00 | $4.92M | open → |
| 2026-08-11 | 2026-08-07 | OrbiMed Capital GP IX LLC Director10% | Buy | 273,333 | $18.00 | $4.92M | open → |
| 2026-08-11 | 2026-08-07 | OrbiMed Genesis GP LLC Director10% | Buy | 273,333 | $18.00 | $4.92M | open → |
| 2026-08-11 | 2026-08-07 | OrbiMed Genesis GP LLC Director10% | Buy | 1,666,667 | $18.00 | $30.00M | open → |
| 2026-08-11 | 2026-08-07 | ORBIMED ADVISORS LLC Director10% | Buy | 1,666,667 | $18.00 | $30.00M | open → |
| 2026-08-11 | 2026-08-07 | OrbiMed Capital GP IX LLC Director10% | Buy | 1,666,667 | $18.00 | $30.00M | open → |
| 2026-08-11 | 2026-08-07 | OrbiMed Capital GP IX LLC Director10% | C | 9,132,420 | $0.00 | $0.00 | open → |
| 2026-08-11 | 2026-08-07 | OrbiMed Genesis GP LLC Director10% | C | 9,132,420 | $0.00 | $0.00 | open → |
| 2026-08-11 | 2026-08-07 | ORBIMED ADVISORS LLC Director10% | C | 9,132,420 | $0.00 | $0.00 | open → |
| 2026-08-10 | 2026-08-07 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. 10% | C | 7,420,091 | $0.00 | $0.00 | open → |
| 2026-08-07 | 2026-08-07 | Forbion Growth Opportunities Fund III Cooperatief U.A. | Buy | 1,680,000 | $18.00 | $30.24M | open → |
| 2026-08-07 | 2026-08-07 | Forbion Growth III Management B.V. | Buy | 1,680,000 | $18.00 | $30.24M | open → |
| 2026-08-07 | 2026-08-07 | Forbion Ventures Fund VII Cooperatief U.A. | Buy | 1,680,000 | $18.00 | $30.24M | open → |
| 2026-08-07 | 2026-08-07 | Forbion Ventures VII Management B.V. | Buy | 1,680,000 | $18.00 | $30.24M | open → |
| 2026-08-07 | 2026-08-07 | Forbion Ventures Fund VII Cooperatief U.A. | Buy | 1,920,000 | $18.00 | $34.56M | open → |
| 2026-08-07 | 2026-08-07 | Forbion Growth III Management B.V. | Buy | 1,920,000 | $18.00 | $34.56M | open → |
| 2026-08-07 | 2026-08-07 | Forbion Growth Opportunities Fund III Cooperatief U.A. | Buy | 1,920,000 | $18.00 | $34.56M | open → |
| 2026-08-07 | 2026-08-07 | Forbion Ventures VII Management B.V. | Buy | 1,920,000 | $18.00 | $34.56M | open → |
| 2026-08-07 | 2026-08-07 | Forbion Growth III Management B.V. | C | 7,990,867 | $0.00 | $0.00 | open → |
| 2026-08-07 | 2026-08-07 | Forbion Growth Opportunities Fund III Cooperatief U.A. | C | 7,990,867 | $0.00 | $0.00 | open → |
| 2026-08-07 | 2026-08-07 | Forbion Ventures Fund VII Cooperatief U.A. | C | 7,990,867 | $0.00 | $0.00 | open → |
| 2026-08-07 | 2026-08-07 | Forbion Ventures VII Management B.V. | C | 7,990,867 | $0.00 | $0.00 | open → |
| 2026-08-07 | 2026-08-07 | Forbion Ventures VII Management B.V. | C | 9,132,420 | $0.00 | $0.00 | open → |
| 2026-08-07 | 2026-08-07 | Forbion Growth Opportunities Fund III Cooperatief U.A. | C | 9,132,420 | $0.00 | $0.00 | open → |
| 2026-08-07 | 2026-08-07 | Forbion Growth III Management B.V. | C | 9,132,420 | $0.00 | $0.00 | open → |
| 2026-08-07 | 2026-08-07 | Forbion Ventures Fund VII Cooperatief U.A. | C | 9,132,420 | $0.00 | $0.00 | open → |
| 2026-08-07 | 2026-08-07 | Rickey James Paul Officer | Buy | 27,777 | $18.00 | $500.0K | open → |
| 2026-08-07 | 2026-08-07 | Viehbacher Christopher Director | Buy | 83,333 | $18.00 | $1.50M | open → |
| 2026-08-07 | 2026-08-07 | Malek David I Director | Buy | 4,166 | $18.00 | $75.0K | open → |
| 2026-08-07 | 2026-08-07 | Anderson Michele A. Officer | Buy | 1,111 | $18.00 | $20.0K | open → |
| 2026-08-07 | 2026-08-07 | Murdoch Travis OfficerDirector | Buy | 83,333 | $18.00 | $1.50M | open → |
| 2026-08-07 | 2026-08-07 | Lubner David Charles Director | Buy | 55,555 | $18.00 | $1000.0K | open → |
Other tickers these insiders trade
Want an email the moment a new insider transaction is filed on BRVE? Set up an alert → Watch4Insider delivers SEC Form 4 alerts with a sub-60s p95 SLA.
